Novocure LTD 8-K filings

Novocure announced record net revenues and active patients for Q2 2026, driven by global growth and the launch of Optune Pax, leading to an upward revision of its full-year financial outlook.

Novocure announced its Optune Pax device has received CE Mark for locally advanced pancreatic cancer, showing improved overall survival and delayed pain progression in a Phase 3 trial.

Novocure's Phase 3 TRIDENT trial for newly diagnosed glioblastoma did not show a statistically significant improvement in overall survival for earlier initiation of Tumor Treating Fields therapy.

NovoCure shareholders elected eleven directors and approved the Amended and Restated 2024 Omnibus Incentive Plan at the 2026 Annual Meeting.

Novocure announced first quarter 2026 financial results, showcasing a 12% year-over-year revenue increase driven by global Optune Gio growth and the promising launch of Optune Pax for pancreatic cancer.

NovoCure Limited filed an amendment to its 8-K detailing the compensation and employment agreement for CEO Frank Leonard.

NovoCure Limited announced an adjustment to the compensation of Dr. Uri Weinberg, who will now serve as Chief Medical Officer in addition to his Chief Innovation Officer role.

Novocure announced positive topline results from its Phase 2 PANOVA-4 trial, demonstrating a statistically significant improvement in disease control rate for metastatic pancreatic cancer.

NovoCure reported an 8% revenue increase in 2025, reaching $655.4 million, and received U.S. FDA approval for Optune Pax to treat locally advanced pancreatic cancer.

NovoCure's U.S. subsidiary had its Medicare billing privileges revoked due to an administrative error, which CMS has now retroactively rescinded.

NovoCure's Optune Pax receives FDA approval for locally advanced pancreatic cancer, marking the first new treatment in nearly 30 years for the condition.

NovoCure's U.S. subsidiary has had its CMS billing privileges revoked due to an administrative issue, leading to an estimated $13 million monthly revenue loss.

Novocure announced preliminary unaudited financial results for Q4 and full year 2025, reporting record annual revenue and outlining key operational and regulatory milestones for 2026.

NovoCure Limited announced a leadership transition with Ashley Cordova resigning as CEO and Director, succeeded by company President Frank Leonard, effective December 1, 2025.

Novocure reported an 8% increase in Q3 2025 net revenues to $167.2 million, driven by active patient growth, and announced the FDA acceptance of its PMA application for pancreatic cancer.

NovoCure's Optune Lua has received approval from Japan's MHLW for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent non-small cell lung cancer.

NovoCure Limited announced the termination of its LUNAR-4 Phase 2 trial for metastatic non-small cell lung cancer, citing the availability of real-world evidence to achieve study objectives.

NovoCure reported second quarter 2025 net revenues of $158.8 million, a 6% year-over-year increase, driven by active patient growth, alongside positive Phase 3 PANOVA-3 clinical trial results for pancreatic cancer.

NovoCure Limited announced the results of its Annual General Meeting, confirming the re-election of eleven directors, the appointment of Francis Leonard as President with a significant RSU award, and the approval of its 2025 Employee Share Purchase Plan.

NovoCure Limited announced positive results from its Phase 3 PANOVA-3 clinical trial, demonstrating a statistically significant improvement in overall survival and quality of life for patients with locally advanced pancreatic adenocarcinoma treated with Tumor Treating Fields therapy combined with chemotherapy.

Novocure announced a 12% year-over-year increase in net revenues for Q1 2025, reaching $155 million, fueled by growth in active patients on Tumor Treating Fields (TTFields) therapy.

NovoCure's Optune Lua has secured CE Mark approval for treating adult patients with metastatic non-small cell lung cancer (mNSCLC) in combination with immune checkpoint inhibitors or docetaxel after progression on platinum-based regimens.

Novocure announces positive financial results for 2024, highlighted by a 19% revenue increase and FDA approval for Optune Lua in metastatic non-small cell lung cancer.

Novocure reports preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million, highlighting growth driven by successful launches and improved approval rates.

NovoCure has formalized the compensation packages for its incoming CEO, Ashley Cordova, and outgoing CEO, Asaf Danziger, as he transitions to a Senior Advisor role.

Novocure's Phase 3 PANOVA-3 trial demonstrated a statistically significant improvement in median overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma using Tumor Treating Fields (TTFields) therapy.

NovoCure reported a 22% year-over-year increase in revenue for the third quarter of 2024, alongside the appointment of a new CFO and the planned retirement of the current CEO.

The FDA has approved Optune Lua for concurrent use with certain therapies in adult patients with metastatic non-small cell lung cancer who have progressed after platinum-based treatment.

NovoCure is undergoing a leadership transition with the current CEO retiring and the CFO stepping into the role, along with other key management changes.

NovoCure announced a 19% year-over-year increase in net revenues for the second quarter of 2024, reaching $150 million, alongside positive clinical trial results.